Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xuekui Gu
Observed names:
X K Gu,
X. gu,
Xue-Kui Gu
Institutions:
Guangzhou University of Chinese Medicine,
First Affiliated Hospital of Guangzhou University of Chinese Medicine
Observed institutions:
Guangzhou University of Chinese Medicine,
Guangzhou University,
First Affiliated Hospital of Guangzhou University of Chinese Medicine
ORCID:
0000-0001-8166-114X
Observed ORCID:
0000-0001-8166-114X
OpenAlex ID:
A5030516210
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
·
Clinical Cancer Research
·
53
Salidroside affects the Th17/Treg cell balance in aplastic anemia via the STAT3/HIF-1α/RORγt pathway
2023
·
Zenghui Liu
, Lixuan Chen
, et al.
·
Redox Report
·
33
PDF
Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia
2020
·
Zenghui Liu
, Xiaoxiong Wu
, et al.
·
Therapeutic Advances in Hematology
·
24
Peripherally inserted central catheter-related bloodstream infections in patients with hematological malignancies: A retrospective 7-years single-center study
2022
·
Tianqi Gao
, Xiangding Zhu
, et al.
·
American Journal of Infection Control
·
17
A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant JAK2 V617F and SETBP1 mutations: a case report and literature review
2020
·
Tianqi Gao
, Changhui Yu
, et al.
·
Therapeutic Advances in Hematology
·
16
PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
2025
·
Peng Sun
, Hong Cen
, et al.
·
Cancer Cell International
·
4
PDF
Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
2021
·
Zhiming Li
, Haiyan Yang
, et al.
·
Blood
·
3
SRC as a Prognostic and Immunomodulatory Biomarker in Acute Myeloid Leukemia: A Multi-Omics Study
2026
·
Jirui Zhong
, Xikun Liu
, et al.
·
International Journal of Molecular Sciences
·
2
PDF
Case Report: A case of non-secretory multiple myeloma presenting with eosinophilia: diagnostic challenges and a focused literature review
2026
·
Jirui Zhong
, Xikun Liu
, et al.
·
Frontiers in Oncology
·
1
PDF
PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial
2023
·
Hang Su
, Tingyu Wang
, et al.
·
Blood
·
1
PDF
Atypical Sweet syndrome: skin sinus tracts in an acutely febrile patient after lymphoma treatment: a case report
2023
·
Shi-Ying Lu
, Hui-Fang Yang
, et al.
·
Frontiers in Immunology
·
1
PDF
Supplementary Table S5 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Figure S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Figure S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Figure S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
2025
·
Tingyu Wang
, Xiuhua Sun
, et al.
Chronic myeloid leukemia with atypical transcript e8a2: a case report and literature review
2025
·
Xikun Liu
, Jirui Zhong
, et al.
·
International Journal of Hematology
[Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation].
2024
·
X Z Li
, R Huang
, et al.
·
PubMed Central
PDF
Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma
2023
·
Tingyu Wang
, Xiuhua Sun
, et al.
·
Blood
Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial
2023
·
Rui Huang
, Xiaonan Lin
, et al.
·
Blood
PDF
Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study
2023
·
Zhiming Li
, Peng Sun
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
57
Citation count:
155
H-index:
5
I10-index:
5
Year
Topic
Type